OPKHealthcare · Diagnostics & ResearchThe 6 Wall Street analysts covering OPKO Health, Inc. hold a median 12-month price target of $3 — +129.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OPKO Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Value (33): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own OPKO Health, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on OPK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +129.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Apr 2026 | Barrington Research | Downgrade | Market Perform | — |
| 2 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 20 Nov 2025 | JP Morgan | Initiates | Neutral | — |
| 31 Oct 2025 | Jefferies | Downgrade | Hold | — |
| 30 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 1 May 2025 | Barrington Research | Maintains | Outperform | — |
| 25 Apr 2025 | JP Morgan | Initiates | Neutral | — |
| 7 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | Barrington Research | Maintains | Outperform | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 26 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | Barrington Research | Maintains | Outperform | — |
| 17 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Sept 2024 | Piper Sandler | Reiterates | Overweight | — |
| 8 Aug 2024 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 57% of US stocks
Cheaper than 77% of US stocks
Cheaper than 87% of US stocks
Higher than 39% of US stocks
Higher than 42% of US stocks
Higher than 62% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Higher than 38% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPK appears on the weeks it earns a place.
Opko Health's stock surged 33% after the company reported a substantial narrowing of its net loss and raised its full-year revenue guidance.
Why it matters — OPK watchers would care because narrowing losses and higher revenue guidance signal potential improvement in the company's financial performance.
OPKO Health beat Q2 estimates, with pharmaceutical growth, Nicoya income, and lower costs narrowing losses and lifting shares pre-market.
Why it matters — An OPK watcher would care because the company exceeded Q2 expectations and showed progress in narrowing losses through operational improvements.
Seeking Alpha published the transcript of OPKO Health's Q2 2026 earnings call.
Why it matters — Earnings call transcripts provide detailed insight into management's commentary on quarterly performance and future outlook.
The article reviews OPKO Health's Q2 2026 earnings performance, comparing the company's top- and bottom-line results as well as key metrics against Wall Street estimates and year-ago figures.
Why it matters — OPK watchers would care because the comparison of key metrics to estimates and prior-year values offers insight into whether the company is meeting market expectations and how its performance trends are evolving.
OPKO Health reported a Q2 loss of $0.01 per share, narrower than the Zacks Consensus Estimate of a $0.08 loss and an improvement from the $0.19 loss a year earlier.
Why it matters — The smaller-than-expected quarterly loss signals improving financial performance for OPKO Health, which investors would watch as a measure of the company's operational progress.
The 6 Wall Street analysts covering OPKO Health, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $8.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering OPKO Health, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OPKO Health, Inc. 79 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, OPKO Health, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +129.0% from the last close, and Ticker Nerd's factor model ranks OPKO Health, Inc. 79 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OPKO Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8.5 over the next 12 months.
OPKO Health, Inc. returned +10.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
OpKO Health Inc. is a multinational biopharmaceutical and diagnostics company operating through two primary segments: Pharmaceuticals and Diagnostics.
The most recent item we track (The Motley Fool, 28 July 2026): "Why Opko Health Stock Surged by 33% on Tuesday". Opko Health's stock surged 33% after the company reported a substantial narrowing of its net loss and raised its full-year revenue guidance.
OpKO Health Inc. is a multinational biopharmaceutical and diagnostics company operating through two primary segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, it develops and commercializes therapies such as Rayaldee, FDA-approved for treating secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, and Somatrogon (hGH-CTP), approved in over 50 markets for growth hormone deficiency in children and adolescents. The company advances multispecific therapies targeting cancers and infectious diseases, partnering with leading pharmaceutical firms to deliver next-generation solutions for serious conditions across global markets. Its Diagnostics segment, primarily through BioReference Health, LLC, provides comprehensive clinical laboratory testing services, including the 4Kscore prostate cancer test, serving physicians, hospitals, clinics, and healthcare facilities nationwide with a network of labs. Founded in 1991 and headquartered in Miami, Florida, OpKO Health Inc. focuses on improving patient outcomes in healthcare and biopharmaceutical sectors.
CEO Dr. Phillip Frost M.D., Ph.D. · 2,275 employees · United States · https://www.opko.com